- €50.59bn
- €45.99bn
- $4.15bn
Brief: ArgenX Shows Positive Vyvgart Results In Adapt Seron Study
Europe Research Roundup: BAE Systems, ITM Power, Lloyds
Argenx tops STOXX on strong gMG drug Vyvgart sales momentum
Brief: Argenx Q2 Net Income USD 245.358 Million
Top of the Street: Handelsbanken, Arkema, Zealand Pharma, SOBI, Argenx
DB expects EU pharma 'malaise' to continue amid US headwinds
Brief: ArgenX Advances Clinical Development Of ARGX-119
ArgenX rises after European Commission approves immune disorder drug
Brief: Argenx Announces European Commission Approval Of Vyvgart Subcutaneous Injection
Europe Research Roundup: Barclays, Carlsberg, Sodexo
Brief: Argenx Presents New Data Highlighting Phase 2 Results In Myositis And Sjogren’S Disease
Europe Research Roundup: AB Dynamics, DHL Group, Gerresheimer
Europe Research Roundup: Adecco Group, Barry Callebaut, EMS Chemie
Argenx down as 'in-line' Q1 results viewed as disappointing amid high expectations
Brief: Argenx Q1 Total Operating Income At $807.37 Mln
Brief: Argenx Says CHMP Recommends EC Approval Of VYVGART For CIDP
Analysis: Trump health policy uncertainty sends biotech sector into deeper slump
ArgenX rises on FDA approval for self-administered Vyvgart syringe
ArgenX rises after 'best case scenario' FDA Vygart approval